Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Nektar Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$139.08M. For fiscal 2025 it was -$139.08M. The highest annual figure on record is $696.73M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$139.08M | – |
| FY2024 | Dec 31, 2024 | -$100.81M | – |
| FY2023 | Dec 31, 2023 | -$256.68M | – |
| FY2022 | Dec 31, 2022 | -$363.97M | – |
| FY2021 | Dec 31, 2021 | -$433.10M | – |
| FY2020 | Dec 31, 2020 | -$412.61M | – |
| FY2019 | Dec 31, 2019 | -$429.04M | -161.6% |
| FY2018 | Dec 31, 2018 | $696.73M | – |
| FY2017 | Dec 31, 2017 | -$47.04M | – |
| FY2016 | Dec 31, 2016 | -$99.66M | – |
| FY2015 | Dec 31, 2015 | -$17.97M | – |
| FY2014 | Dec 31, 2014 | -$3.56M | – |
| FY2013 | Dec 31, 2013 | -$105.86M | – |
| FY2012 | Dec 31, 2012 | -$126.69M | – |
| FY2011 | Dec 31, 2011 | -$108.99M | – |
| FY2010 | Dec 31, 2010 | -$11.70M | – |
| FY2009 | Dec 31, 2009 | -$80.25M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$27.48M | -287.2% |
| Q3 FY2025 | Sep 30, 2025 | -$31.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.11M | – |
| Q4 FY2024 | Dec 31, 2024 | $14.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.82M | – |
| Q4 FY2023 | Dec 31, 2023 | -$32.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$48.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -$132.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$50.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$51.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$149.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$112.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$110.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$109.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$106.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$105.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$109.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$99.81M | – |
| Q2 FY2020 | Jun 30, 2020 | -$74.52M | – |
| Q1 FY2020 | Mar 31, 2020 | -$129.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$108.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$95.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$107.92M | -111.1% |
| Q1 FY2019 | Mar 31, 2019 | -$117.61M | – |
| Q4 FY2018 | Dec 31, 2018 | -$99.29M | – |
| Q3 FY2018 | Sep 30, 2018 | -$95.95M | -230.9% |
| Q2 FY2018 | Jun 30, 2018 | $976.17M | – |
| Q1 FY2018 | Mar 31, 2018 | -$84.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.52M | – |
| Q3 FY2017 | Sep 30, 2017 | $73.28M | – |
| Q2 FY2017 | Jun 30, 2017 | -$46.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$50.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$30.45M | – |
| Q3 FY2016 | Sep 30, 2016 | -$29.03M | – |
| Q2 FY2016 | Jun 30, 2016 | -$34.41M | – |
See a number that looks wrong?